{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:20:54Z","timestamp":1776334854258,"version":"3.51.2"},"reference-count":27,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2021.2376","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T08:04:20Z","timestamp":1629705860000},"source":"Crossref","is-referenced-by-count":6,"title":["Concurrent use of nivolumab and radiotherapy for patients with metastatic non\u2011small cell lung cancer and renal cell carcinoma with oligometastatic disease progression on nivolumab"],"prefix":"10.3892","volume":"15","author":[{"given":"Jawaher","family":"Ansari","sequence":"first","affiliation":[{"name":"Department of Oncology, Prince Sultan Military Medical City, Riyadh 12233, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Farrag","sequence":"additional","affiliation":[{"name":"Department of Oncology, Prince Sultan Military Medical City, Riyadh 12233, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arwa","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Oncology, Prince Sultan Military Medical City, Riyadh 12233, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Abdelgelil","sequence":"additional","affiliation":[{"name":"Department of Oncology, Prince Sultan Military Medical City, Riyadh 12233, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esam","family":"Murshid","sequence":"additional","affiliation":[{"name":"Department of Oncology, Prince Sultan Military Medical City, Riyadh 12233, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulaziz","family":"Alhamad","sequence":"additional","affiliation":[{"name":"Department of Oncology, Prince Sultan Military Medical City, Riyadh 12233, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Oncology, Prince Sultan Military Medical City, Riyadh 12233, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidayath","family":"Ansari","sequence":"additional","affiliation":[{"name":"Department of Imaging, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Hussain","sequence":"additional","affiliation":[{"name":"Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2RX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Glaholm","sequence":"additional","affiliation":[{"name":"Department of Oncology, Royal Marsden Hospital, London SW3 6JJ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"key20210906124811_b1-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20210906124811_b2-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"KEYNOTE-189 investigators: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"key20210906124811_b3-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"key20210906124811_b4-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/cncr.21324","article-title":"The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines","volume":"104","author":"Delaney","year":"2005","journal-title":"Cancer"},{"key":"key20210906124811_b5-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/02841860310010826","article-title":"The swedish council on technology assessment in health care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001-summary and conclusions","volume":"42","author":"Ringborg","year":"2003","journal-title":"Acta Oncol"},{"issue":"1758834017742575","key":"key20210906124811_b6-mco-15-4-02376","doi-asserted-by":"publisher","DOI":"10.1177\/1758834017742575","article-title":"Radiation effects on antitumor immune responses: Current perspectives and challenges","volume":"10","author":"Walle","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"key20210906124811_b7-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20210906124811_b8-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20210906124811_b9-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1200\/JCO.2007.12.4784","article-title":"Patient-reported outcomes and the evolution of adverse event reporting in oncology","volume":"25","author":"Trotti","year":"2007","journal-title":"J Clin Oncol"},{"issue":"254","key":"key20210906124811_b10-mco-15-4-02376","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-01678-1","article-title":"Reprogramming the tumour microenvironment by radiotherapy: Implications for radiotherapy and immunotherapy combinations","volume":"15","author":"Colton","year":"2020","journal-title":"Radiat Oncol"},{"key":"key20210906124811_b11-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-16-1673","article-title":"Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade","volume":"23","author":"Dovedi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20210906124811_b12-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"key20210906124811_b13-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"key20210906124811_b14-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20210906124811_b15-mco-15-4-02376","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/j.ijrobp.2017.06.303","article-title":"Combined immune checkpoint blockade and radiation therapy: timing and dose fractionation associated with greatest survival duration among over 750 treated patients","volume":"99 (Suppl 2)","author":"Samstein","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"S613","key":"key20210906124811_b16-mco-15-4-02376","article-title":"Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): First results of phase II NIVES study","volume":"38 (6 Suppl)","author":"Masini","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20210906124811_b17-mco-15-4-02376","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1200\/JCO.2020.38.6_suppl.614","article-title":"Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC)","volume":"38 (Suppl 6)","author":"Hammers","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20210906124811_b18-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1016\/S1470-2045(19)30171-8","article-title":"Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy","volume":"20","author":"Deutsch","year":"2019","journal-title":"Lancet Oncol"},{"key":"key20210906124811_b19-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijrobp.2020.04.023","article-title":"The promise of combining radiation therapy with immunotherapy","volume":"108","author":"Jagodinsky","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20210906124811_b20-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.adro.2018.05.001","article-title":"Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition","volume":"3","author":"Von Reibnitz","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"key20210906124811_b21-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.lungcan.2019.05.001","article-title":"Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial","volume":"133","author":"Peters","year":"2019","journal-title":"Lung Cancer"},{"key":"key20210906124811_b22-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.critrevonc.2017.01.017","article-title":"The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership","volume":"111","author":"Chajon","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20210906124811_b23-mco-15-4-02376","first-page":"1990","article-title":"Radiation abscopal antitumor effect is mediated through p53","volume":"63","author":"Camphausen","year":"2003","journal-title":"Cancer Res"},{"key":"key20210906124811_b24-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.adro.2018.04.015","article-title":"Multicenter report on toxicities of concurrent nivolumab and radiation therapy","volume":"3","author":"Amin","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"key20210906124811_b25-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijrobp.2017.02.003","article-title":"Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy","volume":"98","author":"Bang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"key20210906124811_b26-mco-15-4-02376","doi-asserted-by":"publisher","DOI":"10.1186\/s41747-019-0134-1","article-title":"Imaging of tumour response to immunotherapy","volume":"4","author":"Dromain","year":"2020","journal-title":"Eur Radiol Exp"},{"key":"key20210906124811_b27-mco-15-4-02376","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.21037\/tlcr-20-1252","article-title":"Immunotherapy beyond progression in patients with advanced non-small cell lung cancer","volume":"9","author":"Ge","year":"2020","journal-title":"Transl Lung Cancer Res"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T19:46:29Z","timestamp":1630957589000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2021.2376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,8,23]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2021.2376","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]},"article-number":"214"}}